HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

IF 1.6 Q4 ONCOLOGY

International Journal of Breast Cancer Pub Date : 2021-05-24 eCollection Date: 2021-01-01 DOI:10.1155/2021/6684629

Tamera J Lillemoe, Mara Rendi, Michaela L Tsai, Monica Knaack, Rina Yarosh, Erin Grimm, Barbara Susnik, Janet Krueger, Susan Olet, Karen K Swenson

{"title":"HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.","authors":"Tamera J Lillemoe, Mara Rendi, Michaela L Tsai, Monica Knaack, Rina Yarosh, Erin Grimm, Barbara Susnik, Janet Krueger, Susan Olet, Karen K Swenson","doi":"10.1155/2021/6684629","DOIUrl":null,"url":null,"abstract":"Objectives: The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship between patterns of HER2 testing results and response to NAC. We evaluated clinicopathologic characteristics associated with RCB categories in HER2+ patients who underwent HER2-directed NAC.Methods: A retrospective chart review was conducted with Stage I-III HER2+ breast cancer cases following NAC and surgical resection. HER2 immunohistochemistry (IHC) staining and fluorescence in situ hybridization (FISH), histologic/clinical characteristics, hormone receptor status, and RCB scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated.Results: 64/151 (42.4%) patients with HER2+ disease had pathologic complete response (pCR). Tumors with suboptimal response (RCB-II and RCB-III) were more likely to demonstrate less than 100% HER2 IHC 3+ staining (p < 0.0001), lower HER2 FISH copies (p < 0.0001), and lower HER2/CEP17 ratios (p = 0.0015) compared to RCB-I and RCB-II responses. Estrogen receptor classification using ≥10% versus ≥1% staining showed greater association with higher RCB categories.Conclusions: HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166502/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2021/6684629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Objectives: The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship between patterns of HER2 testing results and response to NAC. We evaluated clinicopathologic characteristics associated with RCB categories in HER2+ patients who underwent HER2-directed NAC.

Methods: A retrospective chart review was conducted with Stage I-III HER2+ breast cancer cases following NAC and surgical resection. HER2 immunohistochemistry (IHC) staining and fluorescence in situ hybridization (FISH), histologic/clinical characteristics, hormone receptor status, and RCB scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated.

Results: 64/151 (42.4%) patients with HER2+ disease had pathologic complete response (pCR). Tumors with suboptimal response (RCB-II and RCB-III) were more likely to demonstrate less than 100% HER2 IHC 3+ staining (p < 0.0001), lower HER2 FISH copies (p < 0.0001), and lower HER2/CEP17 ratios (p = 0.0015) compared to RCB-I and RCB-II responses. Estrogen receptor classification using ≥10% versus ≥1% staining showed greater association with higher RCB categories.

Conclusions: HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.

Abstract Image

查看原文本刊更多论文

HER2检测特征可以预测HER2阳性乳腺癌新辅助化疗后残留的癌症负担。

目的:her2阳性(+)乳腺癌患者对her2靶向新辅助化疗(NAC)的反应可以通过残余癌症负担(RCB)病理评估来量化，以预测无复发生存期/总生存期。然而，需要更多的信息来描述HER2检测结果模式与NAC反应之间的关系。我们评估了接受HER2定向NAC的HER2+患者与RCB类型相关的临床病理特征。方法:回顾性分析I-III期HER2+乳腺癌NAC和手术切除后的病例。评估HER2免疫组织化学(IHC)染色和荧光原位杂交(FISH)、组织学/临床特征、激素受体状态和RCB评分(RCB-0、RCB- i、RCB- ii和RCB- iii)。结果:151例HER2+患者中有64例(42.4%)有病理完全缓解(pCR)。与RCB-I和RCB-II反应相比，次优反应(RCB-II和RCB-III)的肿瘤更可能表现出低于100%的HER2 IHC 3+染色(p < 0.0001)， HER2 FISH拷贝数较低(p < 0.0001)， HER2/CEP17比率较低(p = 0.0015)。雌激素受体分类≥10%和≥1%染色显示与较高RCB分类有更大的相关性。结论:HER2+特征对治疗的反应不同，尽管它们都被归类为阳性;IHC 3+染色低于100%、HER2 FISH拷贝数较低、HER2/CEP17比值较低的肿瘤可导致较高的RCB评分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Breast Cancer ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.